People · Operator
Named in public records as an officer, director or promoter · active 2011–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eumentis Therapeutics, Inc. | — | Pharmaceuticals | Series A | $11.3M | $36.8M | 2018 |
| JB Therapeutics, Inc. | — | Pharmaceuticals | Pre-Seed | $662K | $31.3M | 2012 |
| Primatope Therapeutics, Inc. | — | Pharmaceuticals | Pre-Seed | $400K | $18.9M | 2011 |
Mark Tepper at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Tepper on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeff Arnold | 1 | 5 |
| James Larrick | 1 | 2 |
| Andrew Pearlman | 1 | 2 |
| Peter Aranow | 1 | 2 |
| Randall Marshall | 1 | 2 |
| Sumner Berstein | 1 | 1 |
| Maryann Bryla | 1 | 1 |
| Kim Patrick | 1 | 1 |
| Amar Kapur | 1 | 1 |
| Keith Reimann | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.